Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of BAT5906 versus Lucentis in neovascular age-related macular degeneration
CTR20221092Phase 3Completed
- Sponsor
- BeiGene
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of BAT5906 in exudative macular degeneration, sponsored by BeiGene. Started Jul 2022; status: completed.
02
Drugs
BAT5906
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20221092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221092.